Home
/
CRISPR Therapeutics AG (CRSP)
Stock Analysis
CRISPR Therapeutics AG (CRSP)
52.61
+5.64%
Updated: 2026-06-16 10:41 UTC
Technology-style analysis layer: price structure, momentum, key levels and business quality in one view.
WOI Investment Thesis
Mixed
Momentum: Neutral
Range: 32% of 52W range
Bull53.01
Base53.01
Bear52.57
Key Levels
Resistance53.01
Support52.57
InvalidationBelow 52.57
Upside Target—
Analyst Narrative
CRISPR Therapeutics AG (CRSP) finished the session at 52.61 (+5.64%). Short-term recovery is improving, but long-term repair is still ongoing. Momentum: +8.68%; 52W position: 31% of range; and Volatility: ATR14 6.14%. RSI(14) stands around 51.5, which keeps the momentum picture broadly balanced. RSI has been trending higher in recent sessions, indicating improving momentum conditions. MACD is positioned under the signal line, suggesting momentum recovery has not fully developed yet. The MACD histogram remains negative, suggesting momentum is still on the softer side.
🎯
Key levels:
The most important nearby levels are support at 52.57 and resistance at 53.01.
🚀
Trigger:
Clearing resistance would improve continuation odds, while slipping below support would weaken the present setup.
Technical Setup
🔺 Technical Setup
Breakout Watch
Downtrend line not broken yet · score 0
🎯 Decision Map
From a roadmap perspective, the setup is boxed by support near 52.12 and resistance around 52.97. A cleaner push through resistance would improve continuation odds, while a loss of support would weaken the current thesis.
Business Lens
💼 Fundamentals Snapshot
Source: sec
💼 Business Lens
QUALITY VIEW
Financial quality snapshot
Financial context is mixed
📈 Growth: Strong
💰 Profit: Negative
💵 Cash: Mixed
🛡 Balance: Manageable
• Quarterly revenue growth remains strong and still points upward.
• Quarterly profitability remains weak, with net margin below zero.
🏢 Company
CRISPR Therapeutics AG
Compare with related stocks
Same sector and industry ideas for deeper research
Note: This is an algorithmic technical snapshot, not financial advice.